Quick summary
Dermorphin is a 7-amino acid frog-skin peptide 30-40x more potent than morphine at the mu-opioid receptor. Its rare D-alanine residue confers metabolic resistance; it gained notoriety in 2012 horse racing doping scandals.
Overview
Dermorphin is a heptapeptide (7 amino acids) isolated from the skin of Phyllomedusa South American tree frogs. It is a potent and selective mu-opioid receptor (MOR) agonist, estimated to be 30–40 times more potent than morphine on a molar basis. A defining structural feature is the presence of a D-amino acid (D-alanine at position 2), which is exceptionally rare in naturally occurring vertebrate peptides and confers metabolic resistance and high receptor affinity. Dermorphin gained notoriety in horse racing doping scandals in 2012.
Mechanism of action
Dermorphin binds mu-opioid receptors with high affinity and selectivity, activating Gi/Go signaling to inhibit adenylyl cyclase, suppress voltage-gated calcium channels, and activate GIRK potassium channels. The result is profound neuronal inhibition in pain pathways including the dorsal horn and periaqueductal gray matter. The D-alanine residue at position 2 increases resistance to aminopeptidase cleavage, extending biological activity compared to endogenous opioid peptides. Dermorphin does not have meaningful affinity at delta or kappa opioid receptors at therapeutic concentrations.
Dosing protocols
| Purpose | Route | Dosage | Frequency | Notes |
|---|---|---|---|---|
| mu-opioid receptor research / pain models (animal) | intravenous | 0.01–1 mg/kg | per experimental protocol | |
| receptor binding / characterization studies | intramuscular | 0.001–0.1 mg/kg | per experimental protocol |
Dosing information is for educational purposes only. Consult a qualified healthcare professional before using any peptide.
Research summary
Dermorphin's extreme potency and selectivity have made it a valuable pharmacological tool for opioid receptor characterization. Research applications include receptor binding studies, pain model experiments, and development of dermorphin-derived analogs with improved pharmacokinetics. Analogs such as DALDA (Tyr-D-Arg-Phe-Lys-NH2) and other modified sequences are studied for targeted analgesia. In 2012, dermorphin was detected in post-race urine samples of multiple racehorses at US tracks, leading to bans and prosecutions. No approved therapeutic applications exist for dermorphin in humans.[1][2][3]
Evidence grading
Each claimed benefit is graded by the strength of available evidence. Grades reflect study quality, not effect size.
Strong = multiple RCTs · Moderate = limited trials or observational · Preliminary = animal or in vitro only · Insufficient = anecdotal or no published data
Side effects
Side effects vary by individual. This is not an exhaustive list. Report unusual symptoms to a healthcare professional.
Common stacks
Peptides commonly paired with Dermorphin for synergistic effects.
Legal status
Dermorphin is available for laboratory research only. It is banned in horse racing competitions by all major regulatory bodies (RMTC, ARCI). It is not approved for human or veterinary therapeutic use.
Sourcing & access
Research compound
Dermorphin is classified as a research compound. Regulatory status varies by jurisdiction. Always verify current legal status and source from vendors providing third-party certificates of analysis (COA).
Frequently asked questions
Dermorphin is a heptapeptide isolated from Phyllomedusa South American tree frogs. It is a potent and selective mu-opioid receptor agonist estimated to be 30-40 times more potent than morphine. Its defining feature is a D-amino acid (D-alanine at position 2), which is exceptionally rare in naturally occurring vertebrate peptides.
Dermorphin binds mu-opioid receptors with high affinity and selectivity, activating Gi/Go signaling to inhibit adenylyl cyclase, suppress calcium channels, and activate potassium channels, producing profound neuronal inhibition in pain pathways. The D-alanine residue increases resistance to aminopeptidase cleavage, extending its biological activity.
Dermorphin carries significant risks including profound analgesia, respiratory depression (the primary danger of mu-opioid agonists), sedation, GI motility reduction, and physical dependence with repeated dosing. It is not approved for human or veterinary therapeutic use.
In 2012, dermorphin was detected in post-race urine samples of multiple racehorses at US tracks, leading to bans and prosecutions. Its extreme potency as a pain-masking agent gave treated horses an unfair competitive advantage. It is banned by all major racing regulatory bodies.